Top

Acta Neurochirurgica

Published in:

01-05-2016 | Clinical Article - Functional

Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases

Authors: Safak Akin, Ilkay Isikay, Figen Soylemezoglu, Taskin Yucel, Alper Gurlek, Mustafa Berker

Published in: Acta Neurochirurgica | Issue 5/2016

Abstract

Background

We report herein a retrospective analysis of the results of 142 consecutive prolactinoma cases operated upon using an endoscopic endonasal trans-sphenoidal approach over a period of 6 years.

Methods

Medical records of 142 cases were analysed with respect to indications for surgery, duration of hospital stay, early remission rates, failures and recurrence rates during a median follow-up of 36 months.

Results

On the basis of magnetic resonance imaging (MRI) data, 19 patients (13.4 %) had microadenoma, 113 (79.6 %) had macroadenoma, and the remaining 10 (7.0 %) had giant adenomas. Cavernous sinus invasion was identified in 25 patients by MRI and confirmed during surgery. Atypical adenoma was diagnosed in 16 patients. Sparsely granulated prolactin adenoma was identified in 99 patients (69.7 %). Our results demonstrate that male sex and higher preoperative prolactin levels are independent factors predicting persistent disease. The post-surgical complications are as follows: 2.8 % patients had meningitis, 2.1 % patients had postoperative cerebrospinal fluid leak and 2.1 % patients had panhypopituitarism. At the end of follow-up, 74.6 % patients went into remission. During follow-up period, five patients who had initial remission developed recurrence.

Conclusions

Our series together with literature data suggest that an endoscopic endonasal trans-sphenoidal approach in the treatment of proloctinomas has a favourable rate of remission. According to the findings of this study, endoscopic endonasal trans-sphenoidal surgery might be an appropriate therapy choice for patients with prolactinoma who could not have been managed with recommended therapeutic modalities.

Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS (2010) Giant prolactinoma and effectiveness of medical treatment. Endocr Pract 16:42–46CrossRefPubMed

Almalki MH, Buhary B, Alzahrani S, Alshahrani F, Alsherbeni S, Alhowsawi G, Aljohani N (2015) Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases. Pituitary 18:405–409CrossRefPubMed

Amar AP, Couldwell WT, Chen JC, Weiss MH (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 97:307–314CrossRefPubMed

Amit Kumar Thotakura AK, Mohana Rao Patibandla MR, Manas K. Panigrahi MK, Gokul Chowdary Addagada GC (2015) Predictors of visual outcome with transsphenoidal excision of pituitary adenomas having suprasellar extension: a prospective series of 100 cases and brief review of the literature. Asian J Neurosurg. doi:10.4103/1793-5482.149995

Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW (2010) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14:222–230CrossRefPubMedCentral

Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82:818–824PubMed

Berezin M, Shimon I, Hadani M (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Investig 18:436–441CrossRef

Berker M, Hazer DB, Yucel T, Gurlek A, Cila A, Aldur M, Onerci M (2012) Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature. Pituitary 15:288–300CrossRefPubMed

Berkmann S, Schlaffer S, Nimsky C, Fahlbusch R, Buchfelder M (2014) Intraoperative high-field MRI for transsphenoidal reoperations of nonfunctioning pituitary adenoma. J Neurosurg 121:1166–1175CrossRefPubMed

10.

Cappabianca P, Cavallo LM, de Divitiis O, de Angelis M, Chiaramonte C, Solari D (2015) Endoscopic endonasal extended approaches for the management of large pituitary adenomas. Neurosurg Clin N Am 26:323–331CrossRefPubMed

11.

Carija R, Vucina D (2012) Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review. CNS Neurol Disord Drug Targets 11:1012–1014CrossRefPubMed

12.

Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG (1978) Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 299:847–852CrossRefPubMed

13.

Chabot JD, Chakraborty S, Imbarrato G, Dehdashti AR (2015) Evaluation of outcomes after endoscopic Endonasal surgery for large and giant pituitary Macroadenoma: a retrospective review of 39 consecutive patients. World Neurosurg 84(4):978–988CrossRefPubMed

14.

Chng E, Dalan R (2013) Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci 20:1637–1643CrossRefPubMed

15.

Choe JH, Lee KS, Jeun SS, Cho JH, Hong YK (2008) Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas. J Korean Neurosurg Soc 44:151–155CrossRefPubMedPubMedCentral

16.

Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8:3–6CrossRefPubMed

17.

Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325–331CrossRefPubMed

18.

Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C (2003) Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol 58:662–670CrossRef

19.

de Paiva Neto MA, Vandergrift A, Fatemi N, Gorgulho AA, Desalles AA, Cohan P, Wang C, Swerdloff R, Kelly DF (2010) Endonasal transsphenoidal surgery and multimodality treatment for giant pituitary adenomas. Clin Endocrinol 72:512–519CrossRef

20.

Dehdashti AR, Ganna A, Witterick I, Gentili F (2009) Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery 64:677–687CrossRefPubMed

21.

Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed

22.

Gnanalingham KK, Bhattacharjee S, Pennington R, Ng J, Mendoza N (2005) The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry 76:415–419CrossRefPubMedPubMedCentral

23.

Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143–153CrossRefPubMed

24.

Hulting AL, Muhr C, Lundberg PO, Werner S (1985) Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand 217:101–109CrossRefPubMed

25.

Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH (2012) Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary 15:150–159CrossRefPubMed

26.

Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol 111:46–52CrossRefPubMed

27.

Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18CrossRefPubMed

28.

Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24:417–423CrossRefPubMed

29.

Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179–1183CrossRefPubMed

30.

Liu JK, Couldwell WT (2004) Contemporary management of prolactinomas. Neurosurg Focus 16, E2PubMed

31.

Lloyd RK, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgeos G, Sano T, Scheithauer BW, Horvath E (2004) Pituitary tumors: introduction. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon

32.

Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170:R213–R227CrossRefPubMed

33.

Maiter D, Primeau V (2012) 2012 update in the treatment of prolactinomas. Ann Endocrinol 73:90–98CrossRef

34.

Martin CH, Schwartz R, Jolesz F, Black PM (1999) Transsphenoidal resection of pituitary adenomas in an intraoperative MRI unit. Pituitary 2:155–162CrossRefPubMed

35.

Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364CrossRef

36.

Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117:421–428CrossRefPubMed

37.

Molitch ME, Thorner MO, Wilson C (1997) Management of prolactinomas. J Clin Endocrinol Metab 82:996–1000CrossRefPubMed

38.

Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P (1996) Prolactinomas resistant to bromocriptine: long term efficacy of quanoglide and outcome of pregnancy. Eur J Endocrinol 135:413–420CrossRefPubMed

39.

Nakao N, Itakura T (2011) Surgical outcome of the endoscopic endonasal approach for non-functioning giant pituitary adenoma. J Clin Neurosci 18:71–75CrossRefPubMed

40.

Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J, Hypopronos (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95:1708–1716CrossRefPubMed

41.

Saeger W (1996) Current pathological classification of pituitary adenomas. Acta Neurochir Suppl 65:1–3PubMed

42.

Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216CrossRefPubMed

43.

Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45:529–537CrossRefPubMed

44.

Schaller B (2005) Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett 26:152–159PubMed

45.

Schwartz TH, Stieg PE, Anand VK (2006) Endoscopic transsphenoidal pituitary surgery with intraoperative magnetic resonance imaging. Neurosurgery 58:ONS44-51

46.

Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156:225–231CrossRefPubMed

47.

Shrivastava RK, Arginteanu MS, King WA, Post KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299–306CrossRefPubMed

48.

Steinmeier R, Fahlbusch R, Ganslandt O, Nimsky C, Buchfelder M, Kaus M, Heigl T, Lenz G, Kuth R, Huk W (1998) Intraoperative magnetic resonance imaging with the magnetom open scanner: concepts, neurosurgical indications, and procedures: a preliminary report. Neurosurgery 43:739–747CrossRefPubMed

49.

Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH (2011) Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol 104:195–204CrossRefPubMed

Title: Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases
Authors: Safak Akin
Ilkay Isikay
Figen Soylemezoglu
Taskin Yucel
Alper Gurlek
Mustafa Berker
Publication date: 01-05-2016
Publisher: Springer Vienna
Published in: Acta Neurochirurgica / Issue 5/2016
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-016-2762-z

2024 ASCO Annual Meeting

Springer Medicine

Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2016

Younger age predicts greater effectiveness of spinal cord stimulation for chronic pain

Cochlear implants in the etiopathogenesis of glioblastoma–an interesting observation or independent finding?

Subthalamic nucleus microelectrode recordings (MER) can be reliably detected despite general anaesthesia and dopaminergic treatment

Early postoperative haematomas in neurosurgery

Current practice of external ventricular drainage: a survey among neurosurgical departments in Germany

The use of surgery for cervical degenerative disease in Norway in the period 2008–2014